What is the Opus Genetics Inc. stock price forecast?

Opus Genetics Inc. is currently trading at $3.90. View real-time AI analysis on Alpha Lenz.

What is Opus Genetics Inc. insider trading activity?

View the latest insider trading data for Opus Genetics Inc. on Alpha Lenz.

What is Opus Genetics Inc.'s P/E ratio?

Opus Genetics Inc.'s P/E ratio is -4.9.

Opus Genetics Inc.

NASDAQ · IRD

$3.90-0.02(-0.51%)Pre-market

Ask about Opus Genetics Inc.'s future dividend policy...

Alpha Chat Insight

“Opus Genetics Inc. trades at a P/E of -4.9 (undervalued) with modest ROE of -449.4%.”

Ask for details →

Company Overview

Opus Genetics Inc. is an innovative biotechnology firm that focuses on the development of gene therapies for inherited retinal diseases. Operating within the burgeoning field of genetic medicine, the company's primary aim is to address sight-threatening conditions that currently have limited or no treatment options. By leveraging cutting-edge genetic research and technology, Opus Genetics Inc. seeks to pioneer treatments that can alter the progression of these diseases at a genetic level. Impacting the healthcare and biopharmaceutical sectors, the company plays a critical role in advancing therapeutic solutions for ocular diseases, positioning itself as a key player in the quest for vision-restoring interventions. With its innovative approach, Opus Genetics Inc. holds potential significance in the market by focusing on unmet clinical needs and contributing to the broader goal of precision medicine.

CEOMr. George Magrath M.B.A., M.D., M.S.

Websitehttps://opusgtx.com

SectorHealthcare

IndustryBiotechnology

Employees18

Company Statistics

FY 2025

Profile

$242.67MMarket Cap

$14.20MRevenue

0.00Shares Out

18Employees

Margins

N/AGross

-257.52%EBITDA

-271.90%Operating

-349.33%Pre-Tax

-349.33%Net

Valuation

-4.89P/E

15.81P/B

17.09EV/Sales

-5.44EV/EBITDA

-6.88P/FCF

Growth (CAGR)

-29.11%Rev 3Yr

N/ARev 5Yr

N/AOp Inc 3Yr

N/AOp Inc 5Yr

N/ANet Inc 3Yr

N/ANet Inc 5Yr

Returns

-113.86%ROA

-449.36%ROE

-110.50%ROIC

Financial Health

$45.09MCash & Cash Equivalents

$-10.20MNet Debt

227.36%Debt/Equity

N/AInterest Cov

Alpha Chat Insight

“Opus Genetics Inc. trades at a P/E of -4.9 (undervalued) with modest ROE of -449.4%.”

Ask for details →

Frequently Asked Questions

Opus Genetics Inc. (ticker: IRD) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 18 employees. Market cap is $243M.

The current price is $3.9 with a P/E ratio of -4.89x and P/B of 15.81x.

ROE is -449.36% and operating margin is -271.90%. Annual revenue is $14M.